GLP-1 RA use is associated with a 38% to 42% lower risk for hepatic complications, including cirrhosis, among those with MASLD and T2D.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results